BMS signs cancer therapy deal worth $1.5bn with Agenus
As part of the agreement, BMS will pay $200m upfront to Agenus, which is also eligible for up to $1.36bn in development, regulatory and commercial milestone payments and
REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence application (BLA) for RGX-121 (clemidsogene lanparvovec) to treat mucopolysaccharidosis II (MPS II), also called Hunter syndrome.